Seeking Alpha

BioLineRx (BLRX +2.3%) says Phase II/III results on BL-1020, an antipsychotic for the treatment...

BioLineRx (BLRX +2.3%) says Phase II/III results on BL-1020, an antipsychotic for the treatment of schizophrenia, are expected during the week of March 18. The interim analysis, which measures the effect of the drug on cognitive function, will be performed on data of approximately 235 randomized patients from 27 sites in Romania and India.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|